NCT07563205Recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer as Part of an Early Access Program
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
The purpose of this observational study is to understand how well a treatment combining chemotherapy and amivantamab works in real life, and how safe it is, in adults with metastatic non-small cell lung cancer (NSCLC) who have certain EGFR gene mutations. The study includes two groups of people: * Group A: people with an EGFR exon 20 insertion who receive amivantamab together with platinum-based chemotherapy as their first treatment, through an early access program. * Group B: people with an EGFR exon 19 or exon 21 mutation who receive amivantamab with platinum-based chemotherapy after having been treated with osimertinib (with or without chemotherapy), also through an early access program. The main question the study wants to answer is: How long can the combination of amivantamab and chemotherapy keep the cancer from coming back or getting worse in these two groups of people? People already receiving amivantamab and chemotherapy for NSCLC through an early access program may be included. They will continue to be followed by their usual oncologist as part of their normal medical care. The study will simply collect their medical information from March 21, 2024 to October 21, 2025. No extra tests or procedures are required. This is an observational study, carried out by the GFPC and partner centers in France.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 20 Apr 2026
- Start date
- 19 Nov 2025
- Primary completion date
- 19 Nov 2027
- Lead sponsor
- GFPC Investigation
- Diseases
- Lung cancer
- NCT number
- NCT07563205
What you commit to
- Study type: Observational
- Planned participants: 100
- From 19 Nov 2025 to the primary completion date, 19 Nov 2027
- 16 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient placed under legal guardianship or subject to a protective legal measure
- Patient who explicitly refuses the collection or use of their personal data for research purposes
- Patient not enrolled, managed, or followed at the investigating site by a qualified site investigator
Who the study is looking for
- Patient over 18 years old
- Cohort A: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion treated with amivantamab-platimum based chemotherapy via an early access program in first line setting.
- Cohort B: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 or 21 treated with amivantamab-platimum based chemotherapy post osimertinib (with or without chemotherapy) via an early access program.
- Patient covered by the French National Health Insurance system or by an approved third-party payer
- Patient who does not object to the collection of their personal data for research purposes (an information sheet will be provided to all living participants; for deceased participants, documented non-opposition in the medical record is not required)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CH du Pays d Aix - Service des Maladies Respiratoires Coordinator of this site? Confirm its status | Aix-en-Provence | France | Recruiting |
| APHP Hôpital Avicennes Coordinator of this site? Confirm its status | Bobigny | France | Recruiting |
| Hôpital Louis Pradel Coordinator of this site? Confirm its status | Bron | France | Active, not recruiting |
| Pneumologie Centre François Baclesse Coordinator of this site? Confirm its status | Caen | France | Active, not recruiting |
| Pneumologie Centre Hospitalier Intercommunal de Créteil Coordinator of this site? Confirm its status | Créteil | France | Recruiting |
| Hôpital A. Mignot Coordinator of this site? Confirm its status | Le Chesnay | France | Recruiting |
| Pneumologie Hôpital Calmette Coordinator of this site? Confirm its status | Lille | France | Recruiting |
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| Pneumologie Hôpital privé Jean Mermoz Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| Hôpital Nord Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
| CHRU de Nancy Coordinator of this site? Confirm its status | Nancy | France | Active, not recruiting |
| Centre Antoine Lacassagne Coordinator of this site? Confirm its status | Nice | France | Active, not recruiting |
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Active, not recruiting |
| CH de la Région d'Annecy - Service de Pneumologie Coordinator of this site? Confirm its status | Pringy | France | Recruiting |
| Pneumologie CHU St Etienne Coordinator of this site? Confirm its status | Saint-Etienne | France | Recruiting |
| CHU La Réunion Site Sud Coordinator of this site? Confirm its status | Saint-Pierre | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.